- Home
- ORGN vs ACET Comparison
ORGN vs ACET Comparison
Compare ORGN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- ACET
- Stock Information
- Founded
- ORGN 2008
- ACET 1947
- Country
- ORGN United States
- ACET United States
- Employees
- ORGN N/A
- ACET N/A
- Industry
- ORGN Major Chemicals
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- ACET Health Care
- Exchange
- ORGN Nasdaq
- ACET Nasdaq
- Market Cap
- ORGN 199.7M
- ACET 93.1M
- IPO Year
- ORGN N/A
- ACET N/A
- Fundamental
- Price
- ORGN $1.01
- ACET $0.91
- Analyst Decision
- ORGN Strong Buy
- ACET Strong Buy
- Analyst Count
- ORGN 1
- ACET 4
- Target Price
- ORGN $3.00
- ACET $5.67
- AVG Volume (30 Days)
- ORGN 1.2M
- ACET 776.5K
- Earning Date
- ORGN 11-14-2024
- ACET 11-06-2024
- Dividend Yield
- ORGN N/A
- ACET N/A
- EPS Growth
- ORGN N/A
- ACET N/A
- EPS
- ORGN N/A
- ACET N/A
- Revenue
- ORGN $35,123,000.00
- ACET N/A
- Revenue This Year
- ORGN $10.27
- ACET N/A
- Revenue Next Year
- ORGN $80.25
- ACET N/A
- P/E Ratio
- ORGN N/A
- ACET N/A
- Revenue Growth
- ORGN 123.12
- ACET N/A
- 52 Week Low
- ORGN $0.44
- ACET $0.81
- 52 Week High
- ORGN $1.90
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- ORGN 30.46
- ACET 37.30
- Support Level
- ORGN $0.95
- ACET $0.81
- Resistance Level
- ORGN $1.28
- ACET $0.98
- Average True Range (ATR)
- ORGN 0.07
- ACET 0.08
- MACD
- ORGN -0.02
- ACET -0.00
- Stochastic Oscillator
- ORGN 3.12
- ACET 31.25
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.